What Alveus Therapeutics does

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapeutics for obesity and metabolic diseases. The company was founded in early 2024 and is headquartered in Philadelphia, Pennsylvania, with research and development operations in Copenhagen, Denmark (Alveus Therapeutics ApS). Alveus is building a multi-modality metabolic pipeline that combines human-genetic-validated target selection with proprietary molecular design. Its lead program, ALV-100, is a novel bifunctional GIPR antagonist / GLP-1R agonist fusion protein licensed from Gmax Biopharm International Limited (global ex-Greater China rights) and is currently in Phase 2 clinical development, having received FDA IND clearance in January 2026. The pipeline also includes ALV-200, a highly selective AMYR3 peptide agonist for once-weekly dosing in IND-enabling studies, an oral amylin small-molecule program, and an undisclosed asset. The company differentiates from current GLP-1 therapies (e.g., Eli Lilly's Zepbound) by pursuing a GIPR-antagonist-plus-GLP-1R-agonist mechanism, and from amylin-class competitors (DACRAs) by emphasizing selectivity, lean-mass preservation, and quarterly dosing potential.

Alveus is a privately held, venture-backed company with no commercial products or revenue. As of February 2026 it has raised a total of $197 million in Series A financing (an initial $159.8M close in January 2026 plus a $37M extension in February 2026), with the syndicate including New Rhein Healthcare Investors (founder and Chairman Nayan Parekh), Andera Partners, Omega Funds, Jeito Capital, Novo Holdings, Sanofi Capital, Kurma Partners, Avego BioScience Capital, Seroba, Global Bioaccess Fund, Sixty Degree Capital, and Agent Capita; Lotte Holdings' Healthcare and Biopharmaceutical CVC added capital in March 2026. The intended end customers are adults with obesity (BMI ≥30) or overweight (BMI ≥25) seeking durable, tolerable, and lower-burden chronic weight management. The company plans to commercialize through traditional pharmaceutical sales channels (specialty pharmacies, providers) once products are approved, with potential supplemental revenue from regional licensing or out-licensing of pipeline assets. The go-to-market today is best characterized as enterprise field-sales and clinical-site activation: enrolling ~180 patients across U.S. Phase 1b sites, building toward Phase 3 initiation in 2027.

Name

Alveus Therapeutics

Legal name

Alveus Therapeutics Inc.

Website

https://alveustx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Alveus Therapeutics is a clinical-stage biotech developing next-generation obesity and metabolic disease therapies. Its lead asset, ALV-100 (a GIPR antagonist/GLP-1R agonist fusion protein), is in Phase 2, with an amylin and oral small-molecule pipeline behind it.

Ownership category

akta.pro rank

Product category

Obesity and Metabolic Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Weight Management & Metabolic OTC (HLAIADAI)

Keywords

• Obesity therapeutics
• Metabolic disease therapies
• Clinical-stage biotechnology
• Fusion protein drugs
• Amylin receptor agonists

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Alveus is developing therapeutic candidates for obesity and metabolic diseases. Upon successful clinical development and regulatory approval, the company intends to commercialize its products (ALV-100, ALV-200, and pipeline candidates) through traditional pharmaceutical sales channels. Revenue would come from product sales to healthcare providers and patients.
2. Licensing and out-licensing: The company acquired global development and commercialization rights outside of greater China to ALV-100 from Gmax Biopharm International Limited in 2024. The company may pursue additional licensing agreements for its proprietary compounds in various geographies as it advances its pipeline.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapeutics for obesity and metabolic diseases. Its lead asset, ALV-100, is a bifunctional GIPR antagonist/GLP-1R agonist fusion protein currently in Phase 2 clinical development. The pipeline also includes ALV-200, a selective amylin receptor 3 (AMYR3) peptide agonist, and an oral amylin small molecule program, all designed to deliver durable weight loss with improved tolerability and lean mass preservation.

Product overview

Alveus Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation therapeutics for obesity and metabolic diseases. The core portfolio includes lead program ALV-100 (a bifunctional GIPR antagonist/GLP-1R agonist fusion protein currently in Phase 2 clinical development), ALV-200 (a selective AMYR3 peptide agonist in IND-enabling stage), an oral amylin small molecule program, and an undisclosed pipeline asset. All programs are designed to address limitations of current obesity treatments, focusing on sustained efficacy, improved tolerability, reduced treatment burden, and superior body composition outcomes compared to existing GLP-1 therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• ALV-100 A bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed for durable weight management with improved quality of weight loss and long-term maintenance. Combines human genetic validation (GIPR loss-of-function variants associated with lower BMI) with a novel molecular architecture. Currently in Phase 2 clinical development for adults with obesity.
• ALV-200 A highly selective amylin receptor 3 (AMYR3) peptide agonist designed to induce weight loss with lean mass preservation and improved tolerability compared to DACRAs. Shows significant selectivity over calcitonin receptor (CTR) while maintaining weight loss efficacy. Designed for once-weekly dosing and targeting the chronic weight management and obesity treatment market. Currently in IND-enabling development.
• Oral Amylin Small Molecule An oral small molecule therapy targeting amylin biology, designed to deliver improved quality of weight loss with superior durability, tolerability, and metabolic outcomes through an oral modality. Part of the differentiated amylin-based pipeline spanning injectable and oral formats for obesity and metabolic disease treatment.

Quantifiable outcome

• Phase 2 data expected by late 2027
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Gmax Biopharm International LimitedcoreTechnology or Integration · 1 January 2024Alveus acquired global development and commercialization rights outside of greater China to ALV-100 from Gmax Biopharm International Limited in 2024. This licensing agreement provided Alveus with its lead clinical candidate.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Amgen: Amgen is developing MariTide (maridebart cafraglutide), a GIPR antagonist/GLP-1R agonist for obesity that mirrors Alveus's ALV-100 mechanism. As a large incumbent with Phase 2/3 data already generated on a similar approach, Amgen is the most direct strategic comparable for validating or invalidating Alveus's core thesis.
• Boehringer Ingelheim: Boehringer Ingelheim has partnered with Zealand Pharma on obesity amylin programs and is a major metabolic-disease incumbent. Comparable as a strategic acquirer/partner candidate and as a comparator on amylin mechanism development.
• Novo Nordisk: Novo Nordisk markets Wegovy and Ozempic, the foundational GLP-1 obesity therapies, and has a deep next-gen pipeline. Alveus's CSO Jacob Jeppesen was former Therapy Area Head at Novo Nordisk, and Novo Holdings is an Alveus investor, making Novo both the dominant commercial incumbent and a strategic counterparty.
• Eli Lilly: Eli Lilly markets Zepbound (tirzepatide), the leading dual GIP/GLP-1 agonist for obesity, and is developing next-generation oral and triple-agonist candidates. Lilly's CBSO Brian Bloomquist came from Eli Lilly's obesity external innovation group, and Lilly represents the primary incumbent ALV-100 must displace commercially.
• Roche: Roche acquired Carmot Therapeutics for its oral GLP-1 and dual-agonist obesity pipeline and is advancing clinical candidates. Comparable as a large incumbent now competing in the obesity space and as a potential acquirer/partner for Alveus's differentiated pipeline.

Direct peers

• Structure Therapeutics: Structure Therapeutics is developing oral small-molecule GLP-1R agonists for obesity and metabolic disease, directly comparable to Alveus's oral amylin small molecule program. Both companies pursue oral alternatives to injectable peptide therapies, addressing similar patient adherence pain points.
• Metsera: Metsera is a clinical-stage obesity biotech with a multi-asset pipeline including peptide and oral amylin programs. Comparable to Alveus in stage (Series A, Phase 1-2), therapeutic focus, and capital intensity, Metsera is a strong comparable for benchmarking Alveus's valuation and clinical trajectory.
• Zealand Pharma: Zealand Pharma is a clinical-stage Danish biotech developing petrelintide, an amylin analog for obesity. Alveus's ALV-200 (selective AMYR3 peptide agonist) directly targets the same amylin pathway, making Zealand the closest mechanistic comparable in the obesity space.
• Keros Therapeutics: Keros Therapeutics is a clinical-stage biotech developing therapies for metabolic and hematologic diseases, with publicly disclosed investor syndicate overlap (Omega Funds, Andera Partners) and a similar pipeline-stage profile to Alveus.

Emerging players

• Rivus Pharmaceuticals: Rivus is a clinical-stage biotech developing controlled metabolic accelerators (CMAs) for obesity and metabolic disease. As an earlier-stage emerging player with a differentiated mechanism, Rivus is a comparable emerging obesity therapeutic competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alveus Therapeutics